In a filing, Karyopharm Therapeutics Inc revealed its President and CEO Paulson Richard A. unloaded Company’s shares for reported $3175.0 on Jan 06 ’25. In the deal valued at $0.78 per share,4,055 shares were sold. As a result of this transaction, Paulson Richard A. now holds 1,124,257 shares worth roughly $0.71 million.
Then, Paulson Richard A. sold 3,620 shares, generating $2,932 in total proceeds. Upon selling the shares at $0.81, the President and CEO now owns 1,128,312 shares.
Before that, Paulson Richard A. sold 3,675 shares. Karyopharm Therapeutics Inc shares valued at $3,346 were divested by the President and CEO at a price of $0.91 per share. As a result of the transaction, Paulson Richard A. now holds 1,131,932 shares, worth roughly $0.71 million.
Piper Sandler initiated its Karyopharm Therapeutics Inc [KPTI] rating to an Overweight in a research note published on January 19, 2023; the price target was $8. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in early November from “a Sector perform” to “an Outperform”. JP Morgan also remained covering KPTI and has increased its forecast on February 09, 2022 with a “Neutral” recommendation from previously “an Underweight” rating.
Price Performance Review of KPTI
On Tuesday, Karyopharm Therapeutics Inc [NASDAQ:KPTI] saw its stock fall -5.89% to $0.63. Over the last five days, the stock has lost -23.62%. Karyopharm Therapeutics Inc shares have fallen nearly -6.37% since the year began. Nevertheless, the stocks have fallen -14.22% over the past one year. While a 52-week high of $1.95 was reached on 01/06/25, a 52-week low of $0.58 was recorded on 01/14/25. SMA at 50 days reached $0.7757, while 200 days put it at $0.9078.
Levels Of Support And Resistance For KPTI Stock
The 24-hour chart illustrates a support level at 0.6110, which if violated will result in even more drops to 0.5888. On the upside, there is a resistance level at 0.6776. A further resistance level may holdings at 0.7220. The Relative Strength Index (RSI) on the 14-day chart is 39.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0265, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.00%. Stochastics %K at 37.72% indicates the stock is a holding.
How much short interest is there in Karyopharm Therapeutics Inc?
A steep rise in short interest was recorded in Karyopharm Therapeutics Inc stocks on 2024-12-31, growing by 0.54 million shares to a total of 19.46 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 18.92 million shares. There was a rise of 2.77%, which implies that there is a positive sentiment for the stock.
